论文部分内容阅读
目的评价XELOX方案新辅助化疗治疗Ⅲ期进展期胃癌的近期疗效及安全性。方法采用单组、开放、非随机方法选择2010年7月至2012年6月47例经影像学检查证实的ⅢA、ⅢB、ⅢC进展期胃癌患者,采用XELOX方案化疗2~3个疗程后评价临床疗效,评估可否手术治疗。结果 14例化疗2疗程后手术,23例化疗3疗程后手术,10例病情进展更换化疗方案,其中行根治性切除术29例,总有效率55.32%。临床受益率为78.72%。不同病理类型胃癌(高、中分化腺癌对比低分化腺癌及印戒细胞癌)对化疗的临床受益率,差异无显著性意义(P>0.05)。化疗过程中最常见的毒副作用为白细胞降低及恶心、呕吐、腹泻、手足综合征。结论 XELOX方案新辅助化疗Ⅲ期进展期胃癌,毒副作用较小,能提高部分患者手术治疗疗效。
Objective To evaluate the short-term efficacy and safety of XELOX regimen neoadjuvant chemotherapy for stage Ⅲ advanced gastric cancer. Methods A total of 47 advanced gastric cancer patients with stage ⅢA, ⅢB and ⅢC confirmed by imaging examination from July 2010 to June 2012 were selected by a single group, open and non-randomized method. The patients were evaluated after 2 to 3 courses of chemotherapy with XELOX regimen Efficacy, assessment of the possibility of surgical treatment. Results 14 cases of chemotherapy after 2 courses of operation, 23 cases of chemotherapy after 3 courses of operation, 10 cases of progression of chemotherapy to replace the program, including radical resection in 29 cases, the total effective rate was 55.32%. The clinical benefit rate was 78.72%. There was no significant difference in the clinical benefit rates of chemotherapy between different pathological types of gastric cancer (high or moderately differentiated adenocarcinoma versus poorly differentiated adenocarcinoma and signet-ring cell carcinoma) (P> 0.05). The most common side effects during chemotherapy are leukopenia and nausea, vomiting, diarrhea and hand-foot syndrome. Conclusion XELOX regimen neoadjuvant chemotherapy stage Ⅲ advanced gastric cancer, fewer side effects, can improve the surgical treatment of some patients.